ERX.NPA.27 Tadalafil (Cialis) - Q3 2017,ERX.NPA.27 ...
[Pages:3]Clinical Policy: Tadalafil (Cialis) Reference Number: ERX.NPA.27 Effective Date: 09.01.17 Last Review Date: 08.17 Line of Business: Commercial
Revision Log
See Important Reminder at the end of this policy for important regulatory and legal information.
Description Tadalafil (Cialis?) is a selective phosphodiesterase type 5 inhibitor.
FDA approved indication Cialis is indicated: For the treatment of erectile dysfunction (ED) For the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) For the treatment of ED and the signs and symptoms of BPH
Limitation of use: If Cialis is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of Cialis decreases from 4 weeks until 26 weeks, and the incremental benefit of Cialis beyond 26 weeks is unknown.
Policy/Criteria Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria
It is the policy of health plans affiliated with Envolve Pharmacy SolutionsTM that Cialis is medically necessary when the following criteria are met:
I. Initial Approval Criteria A. Benign Prostatic Hyperplasia (must meet all): 1. Diagnosis of BPH; 2. Age 18 years; 3. Failure of 2 PDL medications indicated for BPH (e.g., doxazosin, dutasteride, finasteride, prazosin, tamsulosin, terazosin) at up to maximally indicated doses unless all are contraindicated or clinically significant adverse effects are experienced; 4. Dose does not exceed 5 mg per day (1 tablet per day). Approval duration: 12 months
B. Erectile Dysfunction (must meet all): 1. Diagnosis of ED; 2. Age 18 years; 3. Dose does not exceed 1 tablet per dose (8 tablets/month). Approval duration: 12 months
C. Other diagnoses/indications 1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized)
II. Continued Therapy A. All Indications (must meet all): 1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
Page 1 of 3
CLINICAL POLICY Tadalafil
2. Member is responding positively to therapy; 3. If request is for a dose increase, new dose does not exceed:
a. BPH: 5 mg per day (1 tablet per day); b. ED: 1 tablet per dose (8 tablets per month). Approval duration: 12 months
B. Other diagnoses/indications (must meet 1 or 2): 1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy. Approval duration: Duration of request or 12 months (whichever is less); or 2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized)
III. Diagnoses/Indications for which coverage is NOT authorized: A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy ? ERX.PA.01 or
evidence of coverage documents
IV. Appendices/General Information Appendix A: Abbreviation/Acronym Key
BPH: benign prostatic hyperplasia ED: erectile dysfunction
FDA: Food and Drug Administration PDL: preferred drug list
Appendix B: Therapeutic Alternatives
Drug
Dosing Regimen
Doxazosin (Cardura)
1 capsule once daily
Dutasteride (Avodart)*
0.5 mg once daily
Finasteride (Proscar)
5 mg once daily
Prazosin (Minipress)
2 mg twice daily
Tamsulosin (Flomax)
0.4 mg once daily
Terazosin (Hytrin)
5 ? 10 mg once daily
*Only the generic product is on formulary. Avodart requires PA
Dose Limit/ Maximum Dose
8 mg/day 0.5 mg/day 5 mg/day
9 mg/day 0.8 mg/day 20 mg/day
V. Dosage and Administration
Indication
Dosing Regimen
BPH
2.5 - 5 mg once daily
ED
10 - 20 mg as needed prior to sexual
activity or 2.5 mg once daily, without
regard to timing of sexual activity
Maximum Dose 5 mg/day
5 mg/day for ED for once daily use; 20 mg/dose for ED for as needed use, not to exceed 1 dose/24 hours
VI. Product Availability Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg
VII. References 1. Cialis Drug Monograph. Clinical Pharmacology. Accessed June 2017. 2. Cialis Prescribing Information. Indianapolis, IN: Eli Lilly and Company; May 2017. Available at: . Accessed June 23, 2017. 3. McVary KT, Roehrborn CG et al. American Urological Association guideline: management of benign prostatic hyperplasia (BPH). Published 2010; Reviewed and Validity Confirmed 2014. (2010-reviewed-and-validityconfirmed-2014)#x2513. Accessed June 2017.
Page 2 of 3
CLINICAL POLICY Tadalafil
Reviews, Revisions, and Approvals
Policy split from ERX.NSMN.12 Benign prostatic hyperplasia agents and converted to new template. Removed criteria of If request is for non-PDL brand agent, failure of 2 PDL brand agents, unless contraindicated. Added ED criteria.
Date 06/17
P&T Approval Date
08/17
Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.
This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.
This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.
?2017 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.
Page 3 of 3
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- pde5 inhibitors tadalafil sildenafil vardenafil
- public assessment report scientific discussion
- erectile dysfunction ed veterans affairs
- 27 tadalafil cialis q3 2017 27
- efficacy of tadalafil for the treatment of
- 132 tadalafil bph ed cialis
- clinical policy tadalafil cialis
- cialis once a day a new indication
- introduction and welcome
- standard operating procedure for
Related searches
- cialis advertisements
- alternative to cialis and viagra
- cialis alternative drugs
- cialis commercial
- cialis commercials 2017
- best cialis substitute
- cialis tadalafil 20mg
- tadalafil 20mg lowest price
- tadalafil without a doctor s prescription
- cialis tadalafil 20mg reviews
- tadalafil 20 mg reviews
- tadalafil generic india